-
-
-
-
-
-
-
TD Cowen: 'Rocket's protocol modifications may be mitigating prior risks'
-
-
-
-
-
-
-
Morgan Stanley on Rocket Pharmaceuticals (RCKT): approval marks 'positive readthrough to broader pipeline'
-
-
-
-
-
-
-
Rocket Pharmaceuticals (RCKT) PT Lowered to $7 at Leerink Partners
-
-
-
-
-
-
-
Canaccord Genuity Reiterates Buy Rating on Rocket Pharmaceuticals (RCKT)
-
-
-
-
-
-
-
BofA Securities Downgrades Rocket Pharmaceuticals (RCKT) to Neutral
-
-
-
-
-
-
-
ROSEN, A RANKED AND LEADING LAW FIRM, Encourages Rocket Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - RCKT
-
-
-
-
-
-
-
FDA Clinical Hold on RP-A501 Trial Triggers Rocket Pharmaceuticals (RCKT) Stock Plunge and Class Action - Hagens Berman
-
479,045 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All


